A Phase 3 interventional study of IV Acetaminophen and IV Control in Acute Pain, sponsored by Mallinckrodt. Completed at 22 sites in United States. Open to participants aged 1 Day to 2 Years. Per ClinicalTrials.gov, last updated 2020-01-21.
Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing acetaminophen in Acute Pain — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Acute Pain.
Among the 21 studies testing acetaminophen in Acute Pain, this one is the 10th largest by enrollment, is one of 3 that started in 2012, is one of 7 in phase 3, and was the 5th registered.
1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →1 of the 21 studies testing acetaminophen in Acute Pain is open now, in 1 country. Recruiting first, the newest first:
University of Monastir · Sites in Tunisia
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 1 Day to 2 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 162 across the 21 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
Keenova Therapeutics plc has 7 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing acetaminophen in Acute Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy and safety of Intravenous (IV) acetaminophen plus rescue opioids for the relief of moderate to severe acute pain in neonates and infants (age \< 2 years) compared to placebo plus standard of care rescue opioids as well as characterize the concentration-effect relationship (PK/PD) of the intravenous acetaminophen as compared to the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pre-Randomization (Qualification) Inclusion Criteria
Subject has not been administered any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
Drug: IV Acetaminophen
Participants receive a low dose of acetaminophen (IV) for 24 hours
Drug: IV Acetaminophen
Participants receive matching placebo (IV) for 24 hours
Drug: IV Control
IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
Also known as: OFIRMEV
IV Control q6h; 4 doses, in 24 hours
Also known as: Saline, Placebo
Total Rescue Opioid Consumption
Total micrograms per kilogram (µg/kg) of rescue opioid used during the same 24 hours the subject is on study medication
Time frame: in 24 hours
Time to First Rescue Medication
Time frame: within 24 hours
Summary of Pain Intensity Using the Leuven Neonatal Pain Scale (LNPS) in Neonates
The LNPS is used for assessing pain intensity in neonates. Scores on the scale run from 0-14. Higher scores mean worse pain.
Time frame: within 24 Hours
Summary of Pain Intensity Using the LNPS in Younger Infants
The LNPS is used for assessing pain intensity in younger infants. Scores on the scale run from 0-14. Higher scores mean worse pain.
Time frame: within 24 hours
Pain Intensity Using the FLACC Score in Intermediate Aged Infants
The Face, Leg, Activity, Cry, and Consolability (FLACC) scale is used to assess pain intensity in intermediate aged infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.
Time frame: within 24 hours
Pain Intensity Using the FLACC Score in Older Infants
The FLACC scale is used to assess pain intensity in older infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.
Time frame: within 24 hours
| Milestone | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| Started | 61 | 67 | 69 |
| Safety population | 61 | 67 | 69 |
| Modified intent to treat (mitt) | 61 | 67 | 69 |
| Pharmacokinetics evaluable population | 50 | 59 | 58 |
| Completed | 52 | 55 | 52 |
| Not completed | 9 | 12 | 17 |
Total micrograms per kilogram (µg/kg) of rescue opioid used during the same 24 hours the subject is on study medication
| µg/kg | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| Total Rescue Opioid Consumption | 166.9 ± 225.06 | 179.9 ± 193.47 | 180.2 ± 184.70 |
| hours | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| Time to First Rescue Medication | 4.78 (3.15 to 16.32) | 4.76 (2.15 to 10.08) | 3.81 (2.25 to 8.95) |
The LNPS is used for assessing pain intensity in neonates. Scores on the scale run from 0-14. Higher scores mean worse pain.
| score on a scale | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| at 0 hours | 0.8 ± 1.09 | 0.8 ± 1.27 | 1.1 ± 1.26 |
| at 6 hours | 1.1 ± 1.04 | 1.0 ± 1.41 | 1.2 ± 1.82 |
| at 12 hours | 2.2 ± 1.92 | 1.8 ± 1.76 | 2.0 ± 1.83 |
| at 18 hours | 1.0 ± 1.53 | 1.8 ± 1.99 | 0.8 ± 0.99 |
| at 24 hours | 0.8 ± 1.40 | 1.3 ± 1.42 | 0.9 ± 1.40 |
The LNPS is used for assessing pain intensity in younger infants. Scores on the scale run from 0-14. Higher scores mean worse pain.
| score on a scale | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| at 0 hours | 2.1 ± 2.85 | 1.5 ± 1.85 | 2.2 ± 2.05 |
| at 6 hours | 2.1 ± 2.36 | 1.3 ± 1.33 | 2.4 ± 3.10 |
| at 12 hours | 2.2 ± 2.4 | 1.8 ± 1.58 | 1.9 ± 1.24 |
| at 18 hours | 1.6 ± 2.25 | 1.7 ± 2.06 | 2.1 ± 1.44 |
| at 24 hours | 2.3 ± 1.59 | 1.3 ± 1.63 | 2.9 ± 2.51 |
The Face, Leg, Activity, Cry, and Consolability (FLACC) scale is used to assess pain intensity in intermediate aged infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.
| score on a scale | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| at 0 hours | 0.6 ± 1.30 | 1.6 ± 2.27 | 1.2 ± 2.05 |
| at 6 hours | 0.7 ± 0.83 | 2.1 ± 2.71 | 1.4 ± 2.59 |
| at 12 hours | 1.2 ± 1.41 | 0.08 ± 1.39 | 1.8 ± 2.49 |
| at 18 hours | 1.4 ± 2.01 | 0.9 ± 1.19 | 0.5 ± 0.97 |
| at 24 hours | 1.4 ± 2.29 | 0.9 ± 1.56 | 0.3 ± 0.65 |
The FLACC scale is used to assess pain intensity in older infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.
| score on a scale | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| at 0 hours | 2.2 ± 2.64 | 1.8 ± 2.65 | 1.8 ± 2.37 |
| at 6 hours | 0.5 ± 0.90 | 1.2 ± 2.07 | 1.5 ± 2.42 |
| at 12 hours | 0.8 ± 1.27 | 1.7 ± 2.76 | 2.4 ± 1.78 |
| at 18 hours | 1.3 ± 1.95 | 0.1 ± 0.36 | 1.3 ± 2.67 |
| at 24 hours | 2.0 ± 2.59 | 0.8 ± 1.12 | 0.1 ± 0.29 |
Collected over 24 hours. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose Acetaminophen | 0/61 (0%) | 0/61 (0%) | 21/61 (34.4%) |
| High Dose Acetaminophen | 0/67 (0%) | 1/67 (1.5%) | 8/67 (11.9%) |
| Placebo | 0/69 (0%) | 2/69 (2.9%) | 24/69 (34.8%) |
| Event | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| ApneaRespiratory, thoracic and mediastinal disorders | 0/61 | 1/67 | 0/69 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/61 | 0/67 | 1/69 |
| LeucocytosisBlood and lymphatic system disorders | 0/61 | 0/67 | 1/69 |
| Event | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo |
|---|---|---|---|
| PyrexiaGeneral disorders | 3/61 | 3/67 | 13/69 |
| VomitingGastrointestinal disorders | 7/61 | 2/67 | 4/69 |
| TachycardiaCardiac disorders | 0/61 | 0/67 | 6/69 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 5/61 | 0/67 | 3/69 |
| ConstipationGastrointestinal disorders | 3/61 | 2/67 | 2/69 |
| Body temperature increasedInvestigations | 3/61 | 0/67 | 0/69 |
| HypokalaemiaMetabolism and nutrition disorders | 3/61 | 3/67 | 1/69 |
Modified Intent-to-Treat (mITT) population
| Age, Customized(Participants) | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo | Total |
|---|---|---|---|---|
| All Participants — Neonates (birth to ≤ 28 days) | 13 | 12 | 13 | 38 |
| All Participants — Younger infants (≥ 29 days to < 6 mos) | 16 | 20 | 18 | 54 |
| All Participants — Intermediate aged infants (≥ 6 mos to <12 mos) | 18 | 17 | 20 | 55 |
| All Participants — Older infants (≥12 mos to <24 mos) | 14 | 18 | 18 | 50 |
| Sex: Female, Male(Participants) | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo | Total |
|---|---|---|---|---|
| Female | 17 | 27 | 26 | 70 |
| Male | 44 | 40 | 43 | 127 |
| Race (NIH/OMB)(Participants) | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 3 | 4 | 6 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 9 | 9 | 30 |
| White | 40 | 49 | 46 | 135 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 5 | 8 | 18 |
| Region of Enrollment(participants) | Low Dose Acetaminophen | High Dose Acetaminophen | Placebo | Total |
|---|---|---|---|---|
| United States | 61 | 67 | 69 | 197 |
Plan to share: No
The record gives a start of Jun 2012, a primary completion of Aug 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 4 years 5 months after primary completion. A results delay was requested in Aug 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen